US · APLS
Apellis Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Waltham, MA 02451
- Website
- apellis.com
Price · as of 2025-12-31
$40.96
Market cap 2.68B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $48.07 | +17.36% |
| Intrinsic Value(DCF) | $159.44 | +289.26% |
| Graham-Dodd Method(GD) | $3.83 | -90.66% |
| Graham Formula(GF) | $6.27 | -84.69% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $22.26 | ||||
| 2018 | $19.41 | ||||
| 2019 | $34.43 | ||||
| 2020 | $46.66 | $0.00 | $0.00 | ||
| 2021 | $43.30 | $29.12 | $0.00 | $0.00 | $548.83 |
| 2022 | $62.22 | $38.71 | $0.00 | $0.00 | $0.00 |
| 2023 | $61.63 | $67.73 | $13,657.93 | $0.00 | $0.00 |
| 2024 | $25.04 | $46.88 | $102,079.56 | $0.00 | $0.00 |
| 2025 | $20.70 | $48.07 | $5,597.29 | $3.83 | $6.27 |
AI valuation
Our deep-learning model estimates Apellis Pharmaceuticals, Inc.'s (APLS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $48.07
- Current price
- $40.96
- AI upside
- +17.36%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$159.44
+289.26% upside
Graham-Dodd
$3.83
-90.66% upside
Graham Formula
$6.27
-84.69% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| APLS | Apellis Pharmaceuticals, … | $40.96 | 2.68B | +17% | +289% | -91% | -85% | 116.52 | 7.05 | 2.60 | 37.53 | — | 7.05 | 89.81% | 5.52% | 2.23% | 7.48% | 15.34% | 2.28% | 1.31 | 1.25 | 3.14 | 2.58 | 0.26 | -11125.00% | 2846.00% | -15100.00% | 1.73% | 0.14 | 13.42% | 0.00% | 0.00% | 1.53% | 47.40 | 58.37 | 2.62 | 0.17 |
| ADPT | Adaptive Biotechnologies … | $16.02 | 2.46B | +132% | +239% | — | — | -41.11 | 11.18 | 8.83 | -83.74 | — | 24.93 | 74.24% | -20.62% | -21.48% | -28.23% | -33.39% | -11.31% | 1.28 | -4.85 | 3.34 | 3.08 | -7.04 | -6389.00% | 5477.00% | -5050.00% | -2.00% | -0.51 | -28.61% | 0.00% | 0.00% | 0.00% | -43.75 | -51.06 | 9.02 | 2.04 |
| AGIO | Agios Pharmaceuticals, In… | $30.23 | 1.77B | -31% | +212% | — | — | -4.10 | 1.42 | 31.33 | -1.93 | — | 1.42 | 88.26% | -873.87% | -764.01% | -30.20% | -85.25% | -27.89% | 0.05 | — | 11.46 | 10.52 | 0.06 | -16117.00% | 4803.00% | -364.00% | -22.29% | -4.54 | -68.29% | 0.00% | 0.00% | 0.46% | -1.91 | -2.39 | 16.67 | 8.79 |
| BEAM | Beam Therapeutics Inc. | $28.46 | 2.89B | +40% | +284% | -70% | — | -35.47 | 2.29 | 20.31 | -63.04 | — | 2.29 | 84.05% | -274.57% | -57.24% | -8.11% | -231.66% | -6.19% | 0.24 | -8.77 | 13.09 | 12.85 | 0.04 | -8231.00% | 12001.00% | 108.00% | -12.69% | -3.56 | -217.38% | 0.00% | 0.00% | 0.00% | -4.92 | -5.24 | 13.50 | 5.65 |
| CDTX | Cidara Therapeutics, Inc. | $221.38 | 5.61B | -67% | -96% | — | +934% | -0.88 | 0.92 | 117.83 | 0.20 | -0.22 | 0.92 | -6557.49% | -13811.92% | -13319.76% | -218.99% | 567.59% | -120.52% | 0.02 | — | 4.25 | 3.86 | 1.06 | 40952.00% | -9800.00% | 67021.00% | -117.59% | -3.56 | 569.40% | 0.00% | 0.00% | 103.41% | 0.20 | 0.20 | -28.25 | -4.03 |
| CPRX | Catalyst Pharmaceuticals,… | $23.08 | 2.84B | +180% | +200% | -28% | +106% | 13.63 | 3.06 | 4.96 | 6.90 | 48.24 | 3.55 | 85.19% | 43.77% | 36.39% | 25.49% | 84.59% | 21.92% | 0.00 | — | 6.08 | 5.68 | -2.20 | 2824.00% | 1978.00% | -1281.00% | 7.14% | 1.42 | 90.56% | 0.00% | 0.00% | 7.46% | 8.59 | 10.61 | 3.76 | 14.42 |
| IDYA | IDEAYA Biosciences, Inc. | $32.20 | 2.83B | +1,323% | +773% | -84% | — | -25.71 | 2.86 | 13.37 | -14.94 | — | 2.86 | 97.90% | -72.84% | -51.99% | -10.92% | -39.17% | -10.18% | 0.03 | — | 11.34 | 10.87 | 0.55 | -6190.00% | 302443.00% | -7078.00% | -2.51% | -1.21 | -18.06% | 0.00% | 0.00% | 0.67% | -14.51 | -31.47 | 10.57 | 19.76 |
| KNSA | Kiniksa Pharmaceuticals, … | $44.49 | 3.3B | +56% | +8,673% | -74% | +17% | -79.02 | 6.01 | 5.04 | 33.27 | — | 6.18 | 54.63% | 11.40% | 8.71% | -8.59% | 27.89% | -6.43% | 0.02 | — | 3.79 | 3.09 | -1.73 | -22500.00% | 6009.00% | 0.00% | 0.74% | 0.18 | 13.82% | 0.00% | 0.00% | 0.23% | 38.96 | 118.40 | 4.44 | 11.43 |
| MLYS | Mineralys Therapeutics, I… | $29.26 | 1.94B | — | — | — | — | -2.87 | 2.67 | — | -1.62 | -3.42 | 2.67 | 0.00% | — | — | -82.24% | 16423.64% | -77.72% | 0.00 | — | 14.02 | 13.53 | 0.59 | 8392.00% | — | 10501.00% | -32.59% | -11.36 | 14204.87% | 0.00% | 0.00% | 12.69% | -1.62 | -1.88 | — | 16.89 |
| RXRX | Recursion Pharmaceuticals… | $3.67 | 1.47B | +586% | +721% | — | — | -2.52 | 1.44 | 21.75 | -1.71 | — | 2.47 | -61.96% | -867.87% | -863.35% | -59.54% | -127.75% | -44.12% | 0.07 | -358.08 | 5.50 | 5.20 | 1.19 | -1479.00% | 2692.00% | 145.00% | -23.29% | -2.52 | -74.58% | 0.00% | 0.00% | 11.05% | -1.48 | -2.53 | 12.84 | 0.01 |
| SRRK | Scholar Rock Holding Corp… | $44.27 | 4.52B | — | — | — | — | -14.59 | 9.75 | — | -13.57 | -60.50 | 9.81 | 0.00% | — | — | -82.95% | -14081.23% | -62.67% | 0.18 | -36.87 | 9.61 | 9.36 | 0.47 | 2412.00% | — | 3837.00% | -5.59% | -4.28 | -11231.68% | 0.00% | 0.00% | 2.02% | -12.78 | -16.03 | — | 16.84 |
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
- CEO
- Cedric Francois
- Employees
- 705
- Beta
- 0.24
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($159.44 ÷ $40.96) − 1 = +289.26% (DCF, example).